4//SEC Filing
Curnutte John T 4
Accession 0001209191-19-003820
CIK 0001269021other
Filed
Jan 14, 7:00 PM ET
Accepted
Jan 15, 8:11 PM ET
Size
7.3 KB
Accession
0001209191-19-003820
Insider Transaction Report
Form 4
Curnutte John T
Executive Vice President
Transactions
- Tax Payment
Common Stock
2019-01-15$24.25/sh−715$17,339→ 100,485 total - Award
Common Stock
2019-01-12+1,750→ 101,200 total
Footnotes (2)
- [F1]Each Performance Stock Unit ("PSU") granted March 29, 2018 represented a contingent right to receive one share of Issuer's Common Stock. 1,750 PSUs vested upon on January 12, 2019 certification by the Issuer's Compensation Committee of the FDA's December 31, 2018 approval of Andexxa Gen 2 in the United States. An additional 1,750 PSUs will vest on the first anniversary of the Certification Date.
- [F2]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Documents
Issuer
PORTOLA PHARMACEUTICALS INC
CIK 0001269021
Entity typeother
Related Parties
1- filerCIK 0001574589
Filing Metadata
- Form type
- 4
- Filed
- Jan 14, 7:00 PM ET
- Accepted
- Jan 15, 8:11 PM ET
- Size
- 7.3 KB